Neuroscientific Biopharmaceuticals Ltd Cash Flow-to-Debt Ratio
Neuroscientific Biopharmaceuticals Ltd cash flow-to-debt ratio. Neuroscientific Biopharmaceuticals Ltd (NSB) has a Cash Flow-to-Debt Ratio of -3.22x as of June 2025, meaning its operating cash flow of AU$-480.55K could theoretically repay -3% of its total liabilities (AU$149.22K) in one year. Check earnings quality score of Neuroscientific Biopharmaceuticals Ltd to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Neuroscientific Biopharmaceuticals Ltd (2016–2025)
Cash flow-to-debt ratio of Neuroscientific Biopharmaceuticals Ltd from 2016 to 2025. Historical debt coverage capacity for Neuroscientific Biopharmaceuticals Ltd across 10 annual periods. Check how aggressively does Neuroscientific Biopharmaceuticals Ltd reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
Neuroscientific Biopharmaceuticals Ltd Cash Flow-to-Debt Ratio by Year (2016–2025)
Neuroscientific Biopharmaceuticals Ltd cash flow-to-debt ratio by year from 2016 to 2025. Year-by-year debt coverage analysis for Neuroscientific Biopharmaceuticals Ltd. For the full cash flow conversion analysis, see NSB operating cash flow.
| Year | CF-to-Debt Ratio | Operating CF (AUD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -6.31x | AU$-941.33K | AU$149.22K | ▼ -1321.5% |
| 2024 | 0.52x | AU$44.25K | AU$85.68K | ▲ +113.4% |
| 2023 | -3.86x | AU$-2.30 Million | AU$597.36K | ▼ -23.2% |
| 2022 | -3.13x | AU$-6.94 Million | AU$2.22 Million | ▲ +73.1% |
| 2021 | -11.64x | AU$-2.60 Million | AU$223.41K | ▲ +54.8% |
| 2020 | -25.77x | AU$-2.28 Million | AU$88.53K | ▼ -14.4% |
| 2019 | -22.53x | AU$-1.41 Million | AU$62.48K | ▼ -245.6% |
| 2018 | -6.52x | AU$-497.91K | AU$76.39K | ▼ -50.9% |
| 2017 | -4.32x | AU$-186.42K | AU$43.15K | ▼ -501.2% |
| 2016 | -0.72x | AU$-87.76K | AU$122.12K | — |